Voyager Therapeutics
VYGR
52 hedge funds and large institutions have $98.1M invested in Voyager Therapeutics in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 8 reducing their positions, and 2 closing their positions.
275% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 8
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
11% more funds holding
Funds holding: 47 → 52 (+5)
0.42% less ownership
Funds ownership: 41.19% → 40.78% (-0.42%)
33% less capital invested
Capital invested by funds: $146M → $98.1M (-$48.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $45K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$2.42M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.34M |
| 3 |
BlackRock
New York
|
+$1.34M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$917K |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$705K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$6.47M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$3.4M |
| 3 |
JP Morgan Chase
New York
|
-$2.16M |
| 4 |
PIM
Partner Investment Management
San Francisco,
California
|
-$178K |
| 5 |
Morgan Stanley
New York
|
-$109K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$3.18K | -316 | -72% |
|
52
Citigroup
New York
| $1K | +$725 | +72 | +288% |
|
|
53
JP Morgan Chase
New York
| – | -$2.16M | -163,000 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$10K | -745 | Closed |
|
VYGR Hedge Fund Activity: Q2 2017 in Review
52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2017, worth a combined $98.1M — down 33% from $146M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VYGR positions and 2 closed out — a net gain of 5 holders — while 30 added to existing stakes and 8 trimmed.
The largest buyer was Casdin Capital, adding an estimated $2.42M. The largest seller was PFM Health Sciences, cutting an estimated $6.47M.
- 52 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2017, up from 47 in Q1 2017.
- Funds reported $98.1M of Voyager Therapeutics stock for Q2 2017, down 33% quarter-over-quarter.
- 7 funds opened new Voyager Therapeutics positions in Q2 2017 and 2 closed out, a net change of +5 holders.
- The largest Voyager Therapeutics buyer in Q2 2017 was Casdin Capital, an estimated $2.42M added.
- The largest Voyager Therapeutics seller in Q2 2017 was PFM Health Sciences, an estimated $6.47M sold.
Based on aggregated 13F filings for Q2 2017.